Mission of the Pharmaceutical Industry Health and Innovation in the SDGs

(Health UHC) We must achieve Universal Health Coverage (UHC) and access to quality health care to promote physical and mental health and well-being and extend the life span of all people. No one must be left behind. We commit to accelerate the progress achieved to date in reducing neonatal, child, and maternal deaths by eliminating these preventable deaths by 2030. We are committed to ensuring universal access to sexual and reproductive services, including family planning, information and education. We equally accelerate the pace of progress demonstrated against malaria, HIV/AIDS, tuberculosis, hepatitis, Ebola, and other infectious and communicable diseases, including addressing issues related to drug resistance and unaddressed diseases that infest the developing world. We will work to prevent and treat non-communicable diseases, including behavioral, developmental, and neurological disorders, which represent one of the major challenges to sustainable development.

By 2030, we will eradicate communicable diseases such as AIDS, tuberculosis, malaria, and neglected tropical diseases, and address hepatitis, waterborne diseases, and other infectious diseases.

By 2030, reduce by one-third the youth mortality rate from non-communicable diseases through prevention and treatment, and promote mental health and well-being.

Achieve Universal Health Coverage (UHC), including protection from financial risk, access to quality basic health services and access to safe, effective, quality and affordable essential medicines and vaccines for all people.

Support research and development of vaccines and medicines for communicable and non-communicable diseases that primarily affect developing countries. It will also provide access to affordable essential medicines and vaccines in accordance with the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement) and the Doha Declaration on Public Health. The Declaration affirms the right of developing countries to exercise to the fullest extent the flexibility provisions of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement), particularly with respect to the protection of public health and the provision of access to medicines for all.

Develop quality, reliable, sustainable, and resilient infrastructure, including regional and transboundary infrastructure, to support economic development and human welfare, with an emphasis on affordable and equitable access for all.

Promote scientific research and increase technological capacity in the industrial sector in all countries, including developing countries, by fostering innovation and significantly increasing the number of R&D workers per million people by 2030, as well as by increasing public and private R&D spending.

Support domestic technological development, research and innovation in developing countries, including by ensuring a policy environment conducive to industrial diversification and the creation of added value for products.